FBIO - Fortress Biotech, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.8800
+0.2600 (+16.05%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.6200
Open1.5500
Bid0.0000 x 3100
Ask0.0000 x 900
Day's Range1.5300 - 1.9400
52 Week Range0.4900 - 4.5300
Volume3,387,139
Avg. Volume949,817
Market Cap115.248M
Beta (3Y Monthly)4.89
PE Ratio (TTM)N/A
EPS (TTM)-1.9360
Earnings DateMay 8, 2019 - May 13, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.00
Trade prices are not sourced from all markets
  •  ‘Bubble Boy’ Biotech Soars 250 Percent After Cure Announcement
    Bloomberg5 days ago

     ‘Bubble Boy’ Biotech Soars 250 Percent After Cure Announcement

    Mustang Bio, backed by health-care serial entrepreneur Lindsay Rosenwald, has licensed the treatment for the rare disease from St. Jude Children’s Research Hospital, where the treatments took place. Mustang Bio is an offshoot of Fortress Biotech Inc., which is run by Rosenwald and fellow entrepreneur Michael Weiss.

  • GlobeNewswire5 days ago

    St. Jude Children’s Research Hospital publishes results of Lentiviral Gene Therapy for Treatment of Infants with X-linked Severe Combined Immunodeficiency in New England Journal of Medicine

    Mustang Bio, Inc. (“Mustang”) (MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that the New England Journal of Medicine has published data from St. Jude Children’s Research Hospital (“St. Jude”), the nation’s leading hospital dedicated to understanding, treating and curing childhood cancer and other life-threatening diseases. The data comes from a Phase 1/2 clinical trial of a lentiviral gene therapy for the treatment of newly diagnosed infants under two years old with XSCID, also referred to as SCID-X1 and commonly known as bubble boy disease.

  • GlobeNewswire14 days ago

    Mustang Bio to Present at the World Orphan Drug Congress USA 2019

    NEW YORK, April 09, 2019 -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in.

  • GlobeNewswire22 days ago

    Mustang Bio Announces $20 Million Venture Debt Financing Agreement with Horizon Technology Finance

    Mustang Bio, Inc. (“Mustang”) (MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that it has entered into a $20 million debt financing agreement with Horizon Technology Finance Corporation (HRZN) ("Horizon"), a leading specialty finance company that provides capital in the form of secured loans to venture capital-backed companies in the technology, life science, healthcare information and services and cleantech industries.

  • GlobeNewswirelast month

    Fortress Biotech Reports Fourth Quarter and Full-Year 2018 Financial Results and Recent Corporate Highlights

    NEW YORK, March 18, 2019 -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on identifying, in-licensing and developing.

  • GlobeNewswirelast month

    Mustang Bio Reports Full-Year 2018 Financial Results and Recent Corporate Highlights

    NEW YORK, March 18, 2019 -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in.

  • All You Need to Know About Fortress Biotech (FBIO) Rating Upgrade to Strong Buy
    Zackslast month

    All You Need to Know About Fortress Biotech (FBIO) Rating Upgrade to Strong Buy

    Fortress Biotech (FBIO) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • GlobeNewswirelast month

    Mustang Bio to Present at Oppenheimer’s 29th Annual Healthcare Conference

    NEW YORK, March 13, 2019 -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a company focused on the development of novel immunotherapies based on proprietary chimeric antigen.

  • GlobeNewswirelast month

    Avenue Therapeutics Reports Full Year 2018 Financial Results and Recent Corporate Highlights

    NEW YORK, March 12, 2019 -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today.

  • Sarepta (SRPT) Jumps: Stock Rises 8.3%
    Zacks2 months ago

    Sarepta (SRPT) Jumps: Stock Rises 8.3%

    Sarepta (SRPT) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

  • GlobeNewswire2 months ago

    Mustang Bio and Nationwide Children’s Hospital Enter into Exclusive Worldwide License Agreement for Oncolytic Virus (C134) to Treat Glioblastoma Multiforme

    Mustang Bio, Inc. (“Mustang”) (MBIO), a company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology and gene therapies for rare diseases, and Nationwide Children’s Hospital (“Nationwide”), one of America’s largest not-for-profit freestanding pediatric health care systems providing wellness, preventive, diagnostic, treatment and rehabilitative care for infants, children and adolescents, as well as adult patients with congenital disease, announced today that they have partnered and entered into an exclusive worldwide license agreement to develop an oncolytic virus (C134) for the treatment of glioblastoma multiforme. A Phase 1 clinical trial evaluating C134, an attenuated herpes simplex virus type 1 (HSV-1), in recurrent glioblastoma multiforme is being conducted at the University of Alabama at Birmingham (“UAB”).

  • GlobeNewswire2 months ago

    Fortress Biotech Completes Final Stage Closing of the Sale of its Remaining Shares of National Holdings Corporation

    NEW YORK, Feb. 12, 2019 -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on identifying, in-licensing and developing.

  • GlobeNewswire2 months ago

    Avenue Therapeutics Announces First Stage Closing of its Acquisition Agreement with InvaGen (a Cipla subsidiary)

    NEW YORK, Feb. 11, 2019 -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a Fortress Biotech (NASDAQ: FBIO) company, today announced the completion of the first stage.

  • ACCESSWIRE3 months ago

    Biotech on the Brink of Breaking Out

    HENDERSON, NV / ACCESSWIRE / February 5, 2019 / Below are some healthcare plays starting to gain investor interest that could breakout at any time. Do your research now. One of the best examples of the ...

  • ACCESSWIRE3 months ago

    Fortress BioTech, Late Stage Development Progress and Caelum Partnership with Alexion

    NEW YORK, NY / ACCESSWIRE / February 1, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...

  • ACCESSWIRE3 months ago

    Biotechs to Put on Your Watchlist

    HENDERSON, NV / ACCESSWIRE / February 1, 2019 / The biotechnology world is a buzz, 2018's oversold, underperformers are 2019's discounted gems. Below are several biotech stocks that could make you big ...

  • ACCESSWIRE3 months ago

    4 Biotech Stocks Making Moves On Thursday (1/31/19)

    Premier Health Group (OTC:PHGRF) (CSE:PHGI), SCYNEXIS Inc (SCYX), Geron Corporation (GERN), and Fortress Biotech Inc (FBIO) represent four biotech companies creating new treatment technologies aimed to ensure that patients get the therapies best suited to their needs. Premier Health Group (OTC:PHGRF) (CSE:PHGI) announced earlier this week that, further to its news release dated January 10, 2019, the Company has acquired all outstanding securities of Cloud Practice Inc. As a result of the acquisition, Cloud Practice's Founders, including CEO Jordan Visco, and entire support team, consisting of several software developers and sales staff, will join and work alongside the Premier Health team to offer tools and resources providing for better efficiency on a day-to-day basis for both physicians and customers.

  • GlobeNewswire3 months ago

    Fortress Biotech Announces CAEL-101 Strategic Partnership with Alexion Pharmaceuticals

    Fortress Biotech, Inc. (FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that Caelum Biosciences, Inc. (“Caelum”) has signed a strategic agreement with Alexion Pharmaceuticals, Inc. (“Alexion”) (ALXN) to advance the development of CAEL-101 for light chain (AL) amyloidosis. CAEL-101 is a first-in-class amyloid fibril targeted therapy designed to improve organ function by reducing or eliminating amyloid deposits in patients with AL amyloidosis.

  • Zacks Small Cap Research3 months ago

    ATXI: How Much Are CVRs Worth?

    Avenue Therapeutics (ATXI) will hold its special meeting of shareholders on February 6, 2019 to consider the stock purchase and merger agreement proposed by InvaGen Pharmaceuticals. On November 13, 2018, Avenue announced an acquisition with InvaGen Pharmaceuticals which will initially provide $35 million in capital for a one-third stake in the company. Following FDA approval and the desired label, InvaGen will complete its acquisition of the company for an estimated $13.92 per share plus contingent rights to payments related to revenue and profit levels.

  • Have Insiders Been Selling Fortress Biotech, Inc. (NASDAQ:FBIO) Shares?
    Simply Wall St.3 months ago

    Have Insiders Been Selling Fortress Biotech, Inc. (NASDAQ:FBIO) Shares?

    It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders Read More...

  • GlobeNewswire4 months ago

    Report: Exploring Fundamental Drivers Behind Energy Transfer LP, Cable One, DTE Energy, Civitas Solutions, Owens Realty Mortgage, and Fortress Biotech — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Jan. 02, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire4 months ago

    Fortress Biotech Recaps Corporate Highlights and Achievements in 2018

    Fortress Biotech, Inc. (FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today recapped its corporate highlights and achievements in 2018. With over 25 programs in development across six large-market therapeutic areas, we have multiple shots on goal, which allows us to create value while mitigating risk for our shareholders.

  • GlobeNewswire4 months ago

    Mustang Bio Receives Orphan Drug Designation for MB-102 (CD123 CAR T) for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

    Mustang Bio, Inc. (“Mustang”) (MBIO), a company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology and gene therapies for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to MB-102 (CD123 CAR T) for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and incurable blood cancer with a median survival of less than 18 months and no standard of care.

  • GlobeNewswire4 months ago

    Avenue Therapeutics Announces Dosing of First Patient in Second Pivotal Phase 3 Clinical Trial of Intravenous Tramadol for the Management of Postoperative Pain

    Avenue Therapeutics, Inc. (ATXI) (“Avenue”), a specialty pharmaceutical company focused on the development and commercialization of intravenous (IV) tramadol, today announced that the first patient has been dosed in a pivotal Phase 3 clinical trial of IV tramadol for the management of moderate to moderately severe pain in patients following abdominoplasty surgery. This study not only compares the efficacy and safety of IV tramadol to placebo, but also compares the safety and tolerability of IV tramadol to an active comparator (IV morphine),” said Lucy Lu, M.D., Avenue’s President and Chief Executive Officer. The Phase 3, multicenter, randomized, double-blind, three-arm trial will evaluate the efficacy and safety of IV tramadol 50 mg versus placebo.

  • Simply Wall St.4 months ago

    Should You Worry About Fortress Biotech, Inc.’s (NASDAQ:FBIO) CEO Pay?

    Lindsay Rosenwald became the CEO of Fortress Biotech, Inc. (NASDAQ:FBIO) in 2013. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar Read More...